F S&P 500
5,067.00 +20.50 (+0.41%) F Dow Jones
38,187.00 +118.00 (+0.31%) F Nasdaq
17,530.50 +92.25 (+0.53%) E-mini Russell 2000 Index Futur
2,004.20 +14.50 (+0.73%) Petróleo
79.11 +0.11 (+0.14%) Oro
2,333.90 +22.90 (+0.99%)
Panbela Therapeutics, Inc. (PBLA)
Panbela Therapeutics, Inc.
712 Vista Boulevard
Suite 305
Waconia, MN 55387
United States
952 479 1196
https://www.panbela.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 7
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D. | CEO, President & Director | 527k | N/D | 1968 |
| Ms. Susan Horvath | VP of Finance, CFO, Secretary & Treasurer | 452.39k | N/D | 1959 |
| Ms. Tammy Groene | Vice President of Operations | N/D | N/D | N/D |
| Dr. Elizabeth Bruckheimer Ph.D. | VP & Chief Scientific Officer | N/D | N/D | N/D |
Descripción
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Gestión corporativa
La calificación ISS Governance QuickScore de Panbela Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
